Eli Lilly
Lilly dumps Hanmi’s rheumatoid arthritis med
February 20, 2018Manufacturing and Production, Sales and Marketing Eli Lilly, arthritis, hanmi, pharma
Eli Lilly and Hanmi signed an exclusive licensing and collaboration agreement to develop the Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, …
Lilly posts promising P3 Taltz data
February 14, 2018Research and Development Cosentyx, Eli Lilly, IL-17, Novartis, Taltz, biotech, drugs, pharma, pharmaceutical
The IL-17 market is a crowded space, and one dominated by Novartis’ Cosentyx. Eli Lilly is attempting to challenge that, …
MannKind entices Lilly VP to CMO role
February 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, Mannkind, biotech, drugs, pharma, pharmaceutical
MannKind, the California-based biotech, announced that David Kendall would be joining its team as Chief Medical Officer and would be …
Trump nominee and ex-Lilly exec confirmed as US Health Secretary by Senate
January 25, 2018Manufacturing and Production, Medical Communications, Sales and Marketing Alex Azar, Eli Lilly, President trump, Trump, US, pharma
Alex Azar, President’s Trump’s controversial pick for Health and Human Services Secretary (HHS), has been confirmed in the role after …
Eli Lilly’s Taltz get EU approval in psoriatic arthritis subgroup
January 24, 2018Research and Development, Sales and Marketing EU, Eli Lilly, Europe, European Commission, Taltz, pharma, psoriatic arthritis
Eli Lilly has revealed that its IgG4 monoclonal antibody Taltz (ixekizumab) has been awarded marketing approval from the European Commission …
Cyramza fails to improve overall survival in gastric cancer, Lilly scraps regulatory plans
December 11, 2017Research and Development, Sales and Marketing Cancer, Eli Lilly, cyramza, gastric cancer, pharma
Eli Lilly has unveiled Phase 3 results which reveal that its VEGF Receptor 2 antagonist Cyramza (ramucirumab) met its primary …
Sanofi launches patent infringement lawsuit against Mylan over diabetes pen
October 25, 2017Research and Development, Sales and Marketing Basaglar, Eli Lilly, Lantus, Mylan, Sanofi, diabetes, insulin, patent infringement, pharma
Sanofi has launched a lawsuit against Mylan as part of a dispute that alleges that the latter infringed upon 18 …
Lilly looks to leave behind animal health business
October 25, 2017Research and Development, Sales and Marketing Elanco, Eli Lilly, biotech, drugs, pharma, pharmaceutical
Eli Lilly released its Q3 financials and the major talking point was the announcement that the business was reviewing “strategic …
Lilly teams up with CureVac in $1.8 billion cancer vaccine partnership
October 19, 2017Research and Development, Sales and Marketing Cancer, CureVac, Eli Lilly, Vaccine
Eli Lilly has announced it is to partner up with CureVac to leverage its proprietary RNActive technology in order to …
Lilly reveals major senior leadership reshuffle
October 2, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, biotech, drugs, pharma, pharmaceutical
Eli Lilly revealed on 29 September that it would promote four staff members to senior staff positions, and two senior …
Lilly receives FDA breast cancer pill approval, doubts remain
September 29, 2017Medical Communications, Sales and Marketing Eli Lilly, Verzenio, biotech, drugs, pharma, pharmaceutical
Eli Lilly has received an important approval for its breast cancer treatment, Verzenio. The drug will be the third to …
Top Ten most popular articles on Pharmafile.com this week
September 15, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cosentyx, Eli Lilly, Martin Skreli, Teva, pharma, top ten
This week has been a particularly eventful one for the industry: among our top stories, Martin Shkreli finally heads to …
Lilly’s Cyramza combo boasts strong results in bladder cancer
September 11, 2017Research and Development, Sales and Marketing Eli Lilly, bladder cancer, cyramza, immunotherapy, pharma
Eli Lilly has announced new Phase 3 data at the European Society for Medical Oncology 2017 Congress which further add …
Patently problematic? The impact of the Eli Lilly/Actavis intellectual property battle
September 4, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Eli Lilly, biotech, drugs, pemetrexed, pharma, pharmaceutical
The UK Supreme Court has sent shockwaves through the intellectual property world with its recent decision on Eli Lilly v …
Lilly gets second shot at application for ‘blockbuster’ arthritis drug
August 31, 2017Sales and Marketing Eli Lilly, arthritis, baricitinib, biotech, drugs, pharma, pharmaceutical
Earlier this year, Eli Lilly was on the receiving end of one of the most surprising setbacks in recent times …
Latest content
Five Facts about cardiovascular disease
